Status of antidiabetic SGLT-2 inhibitors rise with use in HF
By | translator Alice Kang
22.10.12 06:00:32
가나다라
0
[Interview] Professor Javed Butler (University of Mississippi Medical Center in Jackson) and Professor Seok-Min Kang (Yonsei University College of Medicine)
SGLT-2i clinical data changes heart failure guidelines in the US... is recommended at a higher level in Korea
“Too early to determine whether it is a class effect of SGLT-2 inhibitors...Only Jardiance and Forxiga demonstrated an effect in heart failure yet"
SGLT-2 inhibitors that were initially released as a diabetes treatment have expanded their scope and risen as a representative heart drug. In addition to Heart Failure with reduced EF (HFrEF) and Heart Failure with mildly reduced EF (HFmrEF), SGLT-2 inhibitors have also demonstrated an effect in Heart Failure with Preserved Ejection Fraction (HFpEF), transforming heart failure guidelines in Korea and abroad.
The heart failure treatment effect of SGLT-2 inhibitors, which was first demonstrated with Jardiance (empagliflozin), was confirmed with Forxiga (dapagliflozin). In the EMPEROR-Preserved clinical trial on HFpEF patients, Jardiance succeeded in reaching the primary efficacy endpoint. Then, Forxiga demon
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)